← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,032	+184	+10%	$163B
2	2 Danaher DHR $158B	1,793	+160	+10%	$125B
3	3 Novartis NVS $279B	1,177	+59	+5%	$21.9B
4	4 Illumina ILMN $41B	986	+87	+10%	$49.5B
5	5 Regeneron Pharmaceuticals REGN $80.1B	904	-3	-0.3%	$43.6B
6	6 Agilent Technologies A $49.1B	842	+75	+10%	$31.6B
7	7 Revvity RVTY $17B	598	+67	+13%	$15B
8	8 Charles River Laboratories CRL $14.4B	539	+48	+10%	$11.7B
9	9 DELISTED CATALENT, INC. CTLT	507	+55	+12%	$17.4B
10	10 Sarepta Therapeutics SRPT $1.78B	455	+51	+13%	$12.1B
11	11 Guardant Health GH $21.9B	419	+73	+21%	$11.3B
12	12 ARK Genomic Revolution ETF ARKG $2.05B	415	+173	+71%	$1.83B
13	13 CRISPR Therapeutics CRSP $4.86B	412	+103	+33%	$7.23B
14	14 Ionis Pharmaceuticals IONS $7.1B	383	+15	+4%	$6.8B
15	15 Alnylam Pharmaceuticals ALNY $30B	376	+19	+5%	$14B
16	NVTA 16 DELISTED Invitae Corporation NVTA	351	+66	+23%	$7.25B
17	17 Azenta AZTA $1.63B	316	+47	+17%	$4.87B
18	18 Editas Medicine EDIT $349M	312	+73	+31%	$3.72B
19	19 Arrowhead Research ARWR $8.25B	309	+47	+18%	$5.33B
20	20 10x Genomics TXG $9.52B	305	+86	+39%	$9.38B
21	21 Qiagen QGEN $9.41B	269	+16	+6%	$6.46B
22	22 DELISTED bluebird bio BLUE	262	-13	-5%	$2.69B
23	23 Ultragenyx Pharmaceutical RARE $1.47B	253	+46	+22%	$9.37B
24	24 Adaptive Biotechnologies ADPT $4.09B	251	+45	+22%	$6.75B
25	25 Fate Therapeutics FATE $232M	248	+37	+18%	$7.95B